Bio-Rad Laboratoriesvs.Natera
BIO vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 4.6× larger than Bio-Rad Laboratories by market cap; year to date, Natera leads (+43.1% vs +26.0%).
Side by side
| BIO | NTRA | |
|---|---|---|
| Market cap | $9.7B | $44.6B |
| Price | $390.34 | $336.71 |
| Today | +2.2% | +2.7% |
| Return YTD | +26.0% | +43.1% |
| Return 1Y | +25.7% | +97.9% |
| P/E | 43.5 | — |
| P/S | 3.7 | 16.5 |
| P/B | 1.3 | 24.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More BIO & NTRA comparisons
Other head-to-heads in the Diagnostics segment.
See where BIO and NTRA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →